Successful treatment of in-transit melanoma metastases using topical 2-4 dinitrochlorobenzene

Australasian Journal of Dermatology

Volumn 44, Issue 4, 2003, Pages 277-280

  Von Nida, Jamie ^a   Quirk, Chris ^a  

^a ROYAL PERTH HOSPITAL   (Australia)

Author keywords

Cutaneous malignancy; Immunotherapy; Palliative care

Indexed keywords

1 CHLORO 2,4 DINITROBENZENE; BENZENE DERIVATIVE; NITROGEN;

AGED; ARTICLE; CANCER PALLIATIVE THERAPY; CASE REPORT; CLINICAL FEATURE; CRYOTHERAPY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNOTHERAPY; LIVER METASTASIS; LYMPH NODE METASTASIS; MELANOMA; MELANOMA METASTASIS; TREATMENT OUTCOME; TUMOR REGRESSION;

ADMINISTRATION, TOPICAL; AGED; BIOPSY, NEEDLE; COMBINED MODALITY THERAPY; DINITROCHLOROBENZENE; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; MELANOMA; NEOPLASM STAGING; NEOPLASMS, UNKNOWN PRIMARY; RISK ASSESSMENT; SKIN NEOPLASMS;

EID: 0344255538     PISSN: 00048380     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-0960.2003.00009.x     Document Type: Article

References (17)

1. Coit DG. Recurrent regional metastases and their management. In: Balch MC, Houghton AN, Sober AJ, Soong SJ (eds). Cutaneous Melanoma, 3rd edn. St Louis: Quality Medical, 1998; 301-9.
2. Hersey P. Evaluation of vaccinia viral lysates as therapeutic vaccines in the treatment of melanoma. Ann. NY Acad. Sci. 1993; 690: 167-77.
3. Phan GQ, Attia P, Steinberg SM, White DE, Rosenberg SA. Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J. Clin. Oncol. 2001; 19: 3477-82.
4. Rols MP, Bachaud JM, Giraud P, Chevreau C, Roche H, Teissie J. Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Res. 2000; 10: 468-74.
5. Malek-Mansour S. Remission of melanoma with DNCB treatment. Lancet 1973; 2: 503-4.
6. Illig L, Paul E, Bodeker RH. Epifocal dinitrochlorobenzene therapy in malignant melanoma (experience during the last eight years). Anticancer Res. 1984; 4: 293-8.
7. Cohen MH, Jessup JM, Felix EL, Weese JL, Herberman RB. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: A randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene. Cancer 1978; 41: 2456-63.
8. Klein E. Hypersensitivity reactions at tumor sites. Cancer Res. 1969; 29: 2351-62.
9. Truchetet F, Heid E, Friedel J, Chartier C, Grosshans E. DNCB for malignant melanoma: Significance in the treatment strategy. Anticancer Res. 1989; 9: 1531-6.
10. Roberts DL, Anstey AV, Barlow RJ, Cox NH. UK guidelines for the management of cutaneous melanoma. Br. J. Dermatol. 2002; 146: 7-17.
11. McCarthy WH, Cotton G, Carlon A, Milton GW, Kossard S. Immunotherapy of malignant melanoma: A clinical trial. Cancer 1973; 32: 97-103.
12. Morton D, Eilber FR, Malmgren RA, Wood WC. Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 1970; 68: 158-63.
13. Camacho ES, Pinsky CM, Braun DW, Golbey RB, Fortner JG, Wanebo HJ, Oettgen HF. DNCB reactivity and prognosis in 419 patients with malignant melanoma. Cancer 1981; 47: 2446-50.
14. Nooijen PT, Eggermont AM, Schalkwijk L, Henzen-Logmans S, de Waal RM, Ruiter DJ. Complete response of melanoma intransit metastases after isolated limb perfusion with tumour necrosis factor alpha and melphalan without massive tumour necrosis: A clinical and histopathological study of the delayed-type reaction pattern. Cancer Res. 1998; 58: 4880-7.
15. Catalona WJ, Taylor PT, Rabson AS, Chretien PB. A method for dinitrochlorobenzene contact sensitization: A clinicopathological study. N. Engl. J. Med. 1972; 286: 399-402.
16. Waksman BH. Delayed hypersensitivity reactions: A growing class of immunologic phenomena J. Allergy 1960; 31: 468.
17. Roitt I. Tumour immunology. In: Roitt's Essential Immunology, 9th edn. Oxford: Blackwell Science, 1997; 379-98.